Replies to post #1090 on Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

IMNP @ Stockcharts

Market has been choppy for weeks and IMNP not immune.

Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)

http://ih.advfn.com/p.php?pid=nmona&article=72719816&symbol=IMNP

At the annual meeting, we will ask our holders of Common Stock to:


1. ratify the selection of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016;

2. approve an increase to the amount of shares authorized under the Company’s 2015 Equity Incentive Plan from 5,000,000 to 15,000,000;

3. re-elect each of Mr. Daniel G. Teper and Mr. John Neczesny, nominees for Class III directors, as members of our Board of Directors; and

4. authorize an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a specific ratio, within a range of 1-for- 2 and 1-for- 25, to be determined by our Board of Directors in its sole discretion and effected, if at all, on or before December 16, 2017.


The Board of Directors recommends the approval of each of these proposals.





Investor 100

[Investor100]

Immune Pharmaceuticals (IMNP) Receives FDA Guidance for Phase III Pivotal Trial

POisitve interview with CMO & Principal Owner...positive feedback from FDA...look forward to 2017 for more updates!

Investor 100